Kura Oncology KURA Proceeds from Maturities, Prepayments and Calls of Short-Term Investments
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's proceeds from maturities, prepayments and calls of short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's proceeds from maturities, prepayments and calls of short-term investments?
- Kura Oncology (KURA) reported proceeds from maturities, prepayments and calls of short-term investments of $147.5M in Q1 2026.
- How has Kura Oncology's proceeds from maturities, prepayments and calls of short-term investments changed year-over-year?
- Kura Oncology's proceeds from maturities, prepayments and calls of short-term investments decreased by 12.0% year-over-year, from $167.6M to $147.5M.
- What is the long-term trend for Kura Oncology's proceeds from maturities, prepayments and calls of short-term investments?
- Over 3 years (2022 to 2025), Kura Oncology's proceeds from maturities, prepayments and calls of short-term investments has grown at a 35.4% compound annual growth rate (CAGR), from $303.91M to $755.13M.